All News
Filter News
Found 2,228 articles
-
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
12/30/2022
ValnevaSE, a specialty vaccine company, reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.
-
Moderna Finalizes Strategic Partnership with UK Government
12/21/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced the finalization of a strategic partnership with the UK government to establish a state-of-the-art mRNA research, development, and manufacturing facility in the UK.
-
Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial
12/20/2022
Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Chantal Friebertshauser as Senior Vice President, Commercial, Europe, Middle East and Canada effective January 1, 2023.
-
mRNA Therapeutics Market Size To Hold USD 128.14 Bn By 2030
12/20/2022
The global mRNA therapeutics market size was exhibited at USD 48.1 billion in 2022 and it is expected to hold around USD 128.14 billion by 2030, growing at a CAGR of 13.03% from 2022 to 2030.
-
Pharmaceutical Contract Manufacturing and Research Services Market Size To Hold USD 403 Bn By 2030
12/19/2022
The global pharmaceutical contract manufacturing and research services market size was exhibited at USD 221.95 billion in 2022 and it is expected to hold around USD 403 billion by 2030, growing at a CAGR of 7.74% from 2022 to 2030.
-
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union
12/16/2022
Moderna, Inc.(Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the marketing authorization (MA) to include a booster dose of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), at the dose level for children (6-11 years) of 12.5mcg/12.5mcg (0.25 mL) at least three months after the last prior dose of a COVID-19 vaccine.
-
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
-
Chimeron Bio Appoints Antonin (Tony) de Fougerolles to its Board of Directors
12/15/2022
Chimeron Bio announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors.
-
Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors
12/15/2022
Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors.
-
Comanche Biopharma Announces Appointment of Allison August, M.D., as Chief Medical Officer
12/15/2022
Comanche Biopharma announced that maternal health, vaccine and drug development expert Allison August, M.D., has been appointed as the company´s Chief Medical Officer.
-
Vertex is kicking off a Phase I trial assessing VX-522, an mRNA therapy designed to treat the underlying cause of cystic fibrosis lung disease, while SpliSense is targeting a specific mutation.
-
Senda Biosciences Appoints MIT Institute Professor Paula Hammond, Ph.D., to Its Board of Directors
12/14/2022
Senda Biosciences, Inc. announced the appointment of Paula Hammond, Ph.D., Institute Professor and Head of MIT's Department of Chemical Engineering, to the Company's Board of Directors.
-
An investigational mRNA cancer vaccine developed by Moderna and Merck reached its primary efficacy endpoint, inducing a clinically meaningful improvement in recurrence-free survival.
-
Flagship Pioneering Unveils Montai Health to Treat and Preempt Chronic Disease Afflicting Two Billion People Worldwide
12/13/2022
Flagship Pioneering, the bioplatform innovation company, unveiled Montai Health, a company unlocking the power of nature with its CONECTA™ platform to create medicines that treat and preempt a broad range of chronic diseases.
-
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
12/13/2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940.
-
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
12/12/2022
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease.
-
Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age
12/8/2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children 6 months through 5 years of age.
-
Coronavirus (COVID-19) Update: FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age
12/8/2022
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 vaccines to include use in children down to 6 months of age.
-
In the heated race for a new respiratory syncytial virus vaccine for older adults, Pfizer gained ground on GSK after winning priority review designation for its vaccine candidate.
-
Brad Miller Joins Moderna as Chief Information Officer
12/7/2022
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced the appointment of Brad Miller as Chief Information Officer effective January 3.